Iambic Therapeutics, Inc. — Form 10-Q
Filed November 19, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Iambic Therapeutics is issuing subordinated convertible promissory notes with aggregate principal not exceeding $66,500,000. Each note bears 8% simple interest, matures August 14, 2028, and converts to equity at 80% of preferred financing price, 85% of IPO price (or based on $900M valuation cap), or $3.26/share Series B-4 upon change of control. KKR is a named investor. Notes are subordinated to senior debt.
Why this rating
Financing size unknown relative to company value; standard convertible note terms; no counterparty amounts, deal stage, or current financials disclosed to assess materiality.
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.